Thera-SAbDab

XELIGEKIMAB

> Structural Summary

Therapeutic	Xeligekimab
Target	IL17A
Heavy Chain	EVQLVESGGGLVQPGGSLRLSCAASGMSMSDYWMNWVRQAPGKGLEWVAAINQDGDEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDLISDYYIHYWYFDLWGRGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCRASQNVHNRLTWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNGSPTTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder2.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (Feb '25)	Approved
Estimated Status (Feb '25)	Active
Recorded Developmental Technology
INN Year Proposed	2021
INN Year Recommended	2022
Companies Involved	Genrix Biopharmaceutical
Conditions Approved	Plaque Psoriasis
Conditions Active	Axial spondyloarthritis, Lupus nephritis
Conditions Discontinued	Rheumatoid arthritis
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy